TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03596346

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rapeseed ingredient (RI)
Description: 2 snack bars daily containing 10 g of RI each.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control product without added RI
Description: 2 snack bars daily containing 0 g of RI.
Study: NCT01077765

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Eutrophill
Description: Polyacrylamide Hydrogel
Study: NCT00369031

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human Immunodeficiency Virus glycoprotein 140 (vaccine)
Description: Human Immunodeficiency Virus glycoprotein 140 (vaccine) alone nasally

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: HIV glycoprotein 140 + Labile Toxin mutant LTK63 adjuvant
Description: Human Immunodeficiency Virus glycoprotein 140 (vaccine) + Labile Toxin mutant LTK63 adjuvant nasally

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Labile Toxin mutant LTK63 adjuvant
Description: Labile Toxin mutant LTK63 adjuvant alone
Study: NCT01436721

Intervention type: DEVICE
Group type: NO_INTERVENTION
Intervention: Surgicel® absorbable Haemostat
Description: The raw cut surface was covered with Surgicel® absorbable Haemostat or none but was dried by using fine sutures and an argon beam to achieve complete haemostasis.
Study: NCT03283631

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EGFRvIII-CARs
Description: Gamma-retroviral MSGV1 139 scFv EGFRvIII CAR gene-modified T cells
Study: NCT05480969

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heart failure educational intervention
Description: Educational intervention constitutes of a face-to-face session delivered before hospital discharge and outpatient sessions on regular intervals for a total of 6 months. Outpatient sessions in Intervention group 1 constitute of two home-based sessions on months 1 and 3, combined with weekly telephone calls during month 1 and bi-weekly calls during months 2-6. Outpatient sessions in Intervention group-2 constitute of weekly telephone sessions during month 1 and bi-weekly calls during months 2-6. The pre-discharge session will address self-monitoring and health awareness. Education will be provided by in-person discussion and through printed supporting material. Caregiver education will include understanding heart failure and advice on how to support their patient, manage their own health and well-being and how to get help when needed. During outpatient sessions, repeat education will be done and evaluation of implementation of self-care activities.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heart failure educational intervention
Description: Educational intervention constitutes of a face-to-face session delivered before hospital discharge and outpatient sessions on regular intervals for a total of 6 months. Outpatient sessions in Intervention group 1 constitute of two home-based sessions on months 1 and 3, combined with weekly telephone calls during month 1 and bi-weekly calls during months 2-6. Outpatient sessions in Intervention group-2 constitute of weekly telephone sessions during month 1 and bi-weekly calls during months 2-6. The pre-discharge session will address self-monitoring and health awareness. Education will be provided by in-person discussion and through printed supporting material. Caregiver education will include understanding heart failure and advice on how to support their patient, manage their own health and well-being and how to get help when needed. During outpatient sessions, repeat education will be done and evaluation of implementation of self-care activities.
Study: NCT03521791

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRO-155
Description: PRO-155 (Zebesten ofteno®) Active agent: bromfenac 0.90 mg / mL, dropper bottle of low density polyethylene for multidose administration in the form of an ophthalmic solution of 5 mL (milliliters). Sanitary registry in Mexico: 108M2014~Sodium hyaluronate 0.4% \[Lagricel ofteno®\] 1 drop 3 times a day in the period of vigil in the conjunctival cul-de-sac

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo is constituted by agents, additives and vehicles, of the formulation PRO-155 without pharmacological activity. It is dispensed in dropper bottle of low density polyethylene for multi-dose administration in the form of ophthalmic solution of 5 mL~Sodium hyaluronate 0.4% (Lagricel ofteno®) 1 drop 3 times a day in the period of vigil in the conjunctival cul-de-sac
Study: NCT03313960

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Afrezza plus One Drop | Premium
Description: Participants in this group will receive insulin inhalation, prescribed by their physician, and will also receive One Drop \| Premium (i.e., One Drop \| Experts in-app coaching from a Certified Diabetes Educator (CDE) along with One Drop \| Chrome Bluetooth-connected blood glucose meter that uploads results into the One Drop \| Mobile app and 150 test strips per month for three months).

Intervention type: OTHER
Group type: OTHER
Intervention: One Drop | Premium
Description: Participants in this group will receive One Drop \| Premium (i.e., One Drop \| Experts in-app CDE coaching with the One Drop \| Chrome Bluetooth-connected blood glucose meter that uploads results into the One Drop \| Mobile app and 150 test strips per month for three months).
Study: NCT00650611

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ziprasidone
Description: Period 1: Initial dose of oral ziprasidone suspension 20 mg twice daily, which was titrated up in 20 mg twice daily increments to a maximum dose of 80 mg twice daily by Day 10.~Period 2: patients could switch to oral capsules or remain on oral suspension; doses were flexibly titrated to between 10 and 80 mg twice daily based on the individual needs of the patient as determined by the investigator; concomitant antidepressants and/or mood stabilizers were allowed during Period 2 but not Period 1.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ziprasidone
Description: Period 1: Initial dose of oral ziprasidone suspension 10 mg twice daily, which was titrated up in 10 mg twice daily increments to a maximum dose of 40 mg twice daily by Day 10.~Period 2: patients could switch to oral capsules or remain on oral suspension; doses were flexibly titrated to between 10 and 80 mg twice daily based on the individual needs of the patient as determined by the investigator; concomitant antidepressants and/or mood stabilizers were allowed during Period 2 but not Period 1.
Study: NCT02664155

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban
Description: Direct Oral Anticoagulant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Description: Direct Oral Anticoagulant

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin
Description: Standard Of Care

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: VKA
Description: Standard Of Care
Study: NCT04187092

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: KneeBright Group
Description: The KneeBRIGHT group will use KneeBright device which consists of an EMG biofeedback interface software that guides users through exercise routines. The wireless EMG sensors includes two small electrodes that will be made to stick to the quadriceps muscles both sides. KneeBRIGHT software features a virtual world wherein patients complete challenges controlling the in-game avatar with the EMG units during exercises specific to knee osteoarthritis rehabilitation.~The KneeBRIGHT software will incorporates a variety of exercises for strengthening the quadriceps and will employ algorithms based on the Daily Adjustable Progressive Resistance Exercise (DAPRE) technique, in which the quantity of repetitions performed in these sets is then used to determine the appropriate increase (or possibly decrease) in target resistance for the next sets/sessions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Rehabilitation group
Description: Participants in this group will undergo standard clinic based knee rehabilitation. Both groups will perform exact same exercises, however, no KneeBRIGHT device will be used in this group.
Study: NCT01071187

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: Varenicline 0,5mg daily on day 1-3, Varenicline 1mg daily on day 4-7 and Varenicline 2mg on day 8-84.
Study: NCT01585259

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline
Study: NCT04441463

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sampling for tryptase analysis
Description: 3 bloods test~* One blood sample taking from the mother's vein punction, during the delivery.~* One blood sample tanking from umbilical cord.~* One blood sample taking from the baby in day 3 of life, during the Guthrie test.
Study: NCT01071187

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT00619502

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTaP-IPV-HB-PRP~T vaccine
Description: 0.5 mL, intramuscular (IM)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DTaP-IPV-HB-PRP~T vaccine
Description: 0.5 mL, intramuscular (IM)
Study: NCT05280262

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: CogState Test
Description: Computerized cognitive testing which provides a score/measurement of distinct cognitive functions

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: CogState Test
Description: Computerized cognitive testing which provides a score/measurement of distinct cognitive functions
Study: NCT00373217

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MAGE-A1, Her-2/neu, FBP peptides ovarian cancer vaccine
Description: Given intradermally or subcutaneously
Study: NCT02688517

Intervention type: OTHER
Intervention: Cytology Specimen Collection Procedure
Description: Undergo collection of blood samples

Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT03032783

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation
Description: Undergo Total Body Irradiation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Donor Lymphocyte Infusion
Description: Undergo Donor Lymphocyte Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study: NCT00373217

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MAGE-A1, Her-2/neu, FBP peptides ovarian cancer vaccine
Description: Given intradermally or subcutaneously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tetanus toxoid helper peptide
Description: Given intradermally or subcutaneously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tetanus toxoid helper peptide
Description: Given intradermally or subcutaneously
Study: NCT01643031

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Continued clopidogrel
Description: Patients with low response to clopidogrel randomized to continued clopidogrel treatment will be given an additional 300 mg of clopidogrel loading 1-2 hours before coronary angiography (in addition to the previous 300 mg load or chronic clopidogrel therapy the patient received), followed by 75 mg a day for 1 year after the PCI
Study: NCT02617485

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: 375 mg/m2 IV on day 1 of each 21 days chemotherapy cycle. Number of Cycles: 8.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m2 IV on day 1 of each 21 days chemotherapy cycle. Number of Cycles: 8.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: 50 mg of doxorubicin per square meter administrated IV on day 1 of each chemotherapy cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 50 mg of doxorubicin per square meter administrated IV on day 1 of each chemotherapy cycle
Study: NCT03032783

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo Hematopoietic Stem Cell Transplantation
Study: NCT00412477

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HIV LFn-p24
Description: HIV LFn-p24 is a combination of an Anthrax derived polypeptide Lethal factor (LFn), from which the toxin domain has been removed, and the HIV-1 gag p24 protein has been fused to LFn. Lfn-p24 is formulated in liquid form, and vialed at 200 µg/ml and 600 µglml. The product will be administered IM in doses ranging from 150µg to 450µg with Alhydrogel.
Study: NCT02617485

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine
Description: 1.4 mg of vincristine per square meter, up to a maximal dose of 2 mg, administrated IV on day 1 of each chemotherapy cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: 1.4 mg of vincristine per square meter, up to a maximal dose of 2 mg, administrated IV on day 1 of each chemotherapy cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: 750 mg of cyclophosphamide per square meter of body-surface area administrated IV on day 1 of each chemotherapy cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 750 mg of cyclophosphamide per square meter of body-surface area administrated IV on day 1 of each chemotherapy cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisone
Description: 100 mg of prednisone administrated PO per day for five days, day 1-5 of each chemotherapy cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: 100 mg of prednisone administrated PO per day for five days, day 1-5 of each chemotherapy cycle
Study: NCT04911374

Intervention type: OTHER
Group type: OTHER
Intervention: Gentle Cleansing Lotion, Revision Skincare
Description: Gentle cleansing lotion to be used by study participants

Intervention type: OTHER
Group type: OTHER
Intervention: Aveeno Face Milk SPF 40+
Description: Sunscreen to be applied after application of face moisturizer and eye cream in the morning. Participants were asked to apply the sunscreen if sun exposure was more than 30 minutes per day.
Study: NCT00345644

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risedronate
Description: risedronate sodium 35 mg tablets (once a week dose)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: risedronate placebo
Description: placebo for risedronate tablets (once a week dose)
Study: NCT00412477

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HIV LFn-p24
Description: HIV LFn-p24 is a combination of an Anthrax derived polypeptide Lethal factor (LFn), from which the toxin domain has been removed, and the HIV-1 gag p24 protein has been fused to LFn. Lfn-p24 is formulated in liquid form, and vialed at 200 µg/ml and 600 µglml. The product will be administered IM in doses ranging from 150µg to 450µg with Alhydrogel.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HIV LFn-p24
Description: HIV LFn-p24 is a combination of an Anthrax derived polypeptide Lethal factor (LFn), from which the toxin domain has been removed, and the HIV-1 gag p24 protein has been fused to LFn. Lfn-p24 is formulated in liquid form, and vialed at 200 µg/ml and 600 µglml. The product will be administered IM in doses ranging from 150µg to 450µg with Alhydrogel.
Study: NCT03886844

Intervention type: DIETARY_SUPPLEMENT
Intervention: Human milk fortifier based on human milk (Prolacta)
Description: Intervention is started with an enteral intake of 100 ml/kg until 32 weeks corrected for prematurity, afterwards a human milk fortifier based on bovine milk is administered until estimated date of birth or 52 weeks corrected for prematurity (weight \<10. percentile) according to ESPGHAN(=European Society for paediatric gastroenterology, hepatology and nutrition) guidelines
Study: NCT03054363

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tucatinib in Combination with Palbociclib and Letrozole
Description: Starting dose of combination therapy :~Tucatinib 300 mg PO BID Palbociclib 125 mg PO daily 21 day on, 7 days off Letrozole 2.5 mg PO daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tucatinib in Combination with Palbociclib and Letrozole
Description: Subjects Tucatinib 300 mg PO BID Palbociclib 75mg PO daily 21 days on followed by 7 days off Letrozole 2.5 mg PO daily.
Study: NCT00522067

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adjuvanted influenza vaccine
Description: Vaccination with MF 59 adjuvanted trivalent seasonal influenza vaccine
Study: NCT01151683

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: magnesium
Description: Magnesium chelate, 300mg (2 capsules of 150mg) twice a day, per oral Total of 600mg per day

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Two capsules of placebo per oral twice a day
Study: NCT00826813

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Esophageal stent placement
Description: The esophageal stent combined a self-expandable covered esophageal stent and 125I radioactive seeds. Sheathes were attached to the outer surface of the stent, containing 125I radioactive seeds of CIAE 6711. The seeds were loaded into the sheathes on the stent immediately before implantation of the stent. The numbers and dose of the radioactive stent seeds was determined by the treatment plan system based on the size of the individual tumor. To cover the entire lesion of the tumor by the sheaths containing 125I seeds, at least 2 cm exceeding the tumor margins was required. The distance between the two sheaths was 15mm. In the control group, conventional covered esophageal stents were used which provided by the same company as those attached with 125I seeds.
Study: NCT00404521

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PM02734
Description: Administered every 3 weeks, intravenously, over 30 minutes
Study: NCT03968419

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canakinumab
Description: 200 mg of canakinumab administered via subcutaneous injections once every 3 weeks for a maximum duration of 6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canakinumab
Description: 200 mg of canakinumab administered via subcutaneous injections once every 3 weeks for a maximum duration of 6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg of pembrolizumab administered via infusion once every 3 weeks for a maximum duration of 6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg of pembrolizumab administered via infusion once every 3 weeks for a maximum duration of 6 weeks
Study: NCT03446495

Intervention type: DRUG
Intervention: Trabectedin + PLD
Description: Combination of Trabectedin + PLD: PLD 30 mg/m2 intravenous (IV) infusion over 90 minutes + trabectedin 1.1 mg/m2 IV infusion over 3 hours every 3 weeks.
Study: NCT02964637

Intervention type: OTHER
Intervention: Observational Study
Study: NCT00373217

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV
Study: NCT02964637

Intervention type: OTHER
Intervention: Observational Study

Intervention type: OTHER
Intervention: Observational Study

Intervention type: OTHER
Intervention: Observational Study

Intervention type: OTHER
Intervention: Observational Study

Intervention type: OTHER
Intervention: Observational Study

Intervention type: OTHER
Intervention: Observational Study
Study: NCT04268888

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab and TACE/TAE
Description: Immunotherapy and TACE/TAE

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TACE/TAE
Description: TACE/TAE (as per local practice)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TACE/TAE
Description: TACE/TAE (as per local practice)
Study: NCT01533727

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Autologous CIK Transfusion plus Chemotherapy
Description: vinorelbine 25-30mg/m2 d1, d8 q3w; DDP 75mg/m2 d1 q3w; pemetrexed 500mg/m2 d1 q3w; carboplatin AUC 5/6 q3w; CIK infusion D14 q3w

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chemotherapy alone
Description: vinorelbine 25-30mg/m2 d1, d8 q3w; DDP 75mg/m2 d1 q3w; pemetrexed 500mg/m2 d1 q3w; carboplatin AUC 5/6 q3w;
Study: NCT02395549

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.375% (w/w) MTC896 Gel
Description: 0.375% (w/w) MTC896 Gel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.75% (w/w) MTC896 Gel
Description: 0.75% (w/w) MTC896 Gel
Study: NCT00373217

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Description: Patients undergo primary optimal cytoreductive surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Description: Patients undergo primary optimal cytoreductive surgery
Study: NCT03942120

Intervention type: DRUG
Intervention: Ustekinumab
Description: Participants treated with ustekinumab under real world clinical practice will be observed in this study. No study drug will be administered as a part of this study.
Study: NCT02046746

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral Nutritional Supplement (ONS)
Description: renal specific commercially available ONS
Study: NCT01790347

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise group
Description: The physical conditioning program included a total of three 50-55 minute sessions per week. Pregnant women started at 9 weeks and finished at 38-39 weeks, therefore, an average of 85 training sessions were planned for each participant. All subjects wore a heart rate (HR) monitor (Polar FT7, Finland) during the training sessions to ensure that the exercise intensity was light to moderate.~Each session included 10 min of warm up and 10 min of cool down which included an specific pelvic floor muscles training. The core section of the exercise session lasted from 25 to 30 min and included moderate-intensity aerobic exercises once a week and resistance exercises twice a week.
Study: NCT03522675

Intervention type: DEVICE
Group type: OTHER
Intervention: NeoMatriX Wound MatriX Collagen Dressing
Description: Collagen wound dressing
Study: NCT01882647

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 000-0551 Lotion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Lotion